MNDA

Across TCGA pan-cancer cohorts, MNDA mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MNDA data layer compared with 25 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MNDA mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MNDA expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

CCRCC, LUAD, and COAD are the cancer types where MNDA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	III,IV	0.660	1.000	.014	12	view →
LUAD	OS	Tertile	III,IV	0.317	0.815	.001	12	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
HNSC	DFS	Tertile	All	1.000	0.623	.040	6	view →
UCEC	OS	Median	II,III,IV	1.000	0.628	.013	6	view →
LSCC	OS	Tertile	All	0.970	0.838	.042	2	view →
PDAC	DFS	Median	III,IV	0.489	0.224	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MNDA–CCRCC (OS)

Open the CCRCC breakdown →